Related Experiment Video
Updated: Jun 23, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and
Claire Gibrat1, Martine Saint-Pierre, Mélanie Bousquet
1Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, Québec, Canada.
Abstract:
Animal models are invaluable tools to study neurodegenerative disorders but a general consensus on the most accurate rodent model of Parkinson's disease has not been reached. Here, we examined how different methods of MPTP administration influence the degeneration of the dopaminergic (DA) system. Adult male C57BL/6 mice were treated with the same cumulative dose of MPTP following four distinct procedures: (i) subacute i.p. injections; (ii) 28-day chronic s.c. infusion; (iii) 28-day chronic i.p. infusion; and (iv) 14-day chronic i.p. infusion. Subacute MPTP treatment significantly affected all aspects of the DA system within the nigral and striatal territories. In contrast, the 28-day chronic s.c. infusion did not significantly alter any components of the DA system. The 28- and 14-day chronic i.p. infusions induced loss of tyrosine hydroxylase (TH)-positive cells correlated with a decrease in Nurr1 mRNA levels, but no significant decrease in the density of TH striatal fibers. Importantly, however, only the 14-day chronic MPTP i.p. infusion protocol promoted the formation of neuronal inclusions as noted by the expression of alpha-synuclein protein within the cytoplasm of TH nigral neurons. Overall, we found that the 14-day chronic MPTP i.p. infusion reproduces more accurately the pathological characteristics of early stage Parkinson's disease.
Insights
The 14-day chronic MPTP i.p. infusion in mice best models Parkinson's disease pathology. This method accurately replicates early-stage neurodegeneration and alpha-synuclein inclusions, crucial for studying Parkinson's disease.
Area of Science:
- Neuroscience
- Toxicology
- Pathology
Background:
- Parkinson's disease (PD) research relies on animal models, but consensus on the most accurate rodent model is lacking.
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to induce parkinsonian symptoms in rodents.
- Different MPTP administration methods yield varying results, necessitating a comparison of protocols.
Purpose of the Study:
- To investigate how distinct MPTP administration methods impact the dopaminergic (DA) system in mice.
- To identify an MPTP administration protocol that most accurately replicates early-stage Parkinson's disease pathology.
Main Methods:
- Adult male C57BL/6 mice received the same cumulative MPTP dose via four different protocols: subacute i.p. injections, 28-day chronic s.c. infusion, 28-day chronic i.p. infusion, and 14-day chronic i.p. infusion.
- Evaluated degeneration of the dopaminergic system, including tyrosine hydroxylase (TH)-positive cells and striatal fibers.
- Assessed neuronal inclusions via alpha-synuclein protein expression.
Main Results:
- Subacute MPTP injections significantly impacted the nigral and striatal DA system.
- Chronic s.c. infusion showed no significant DA system alterations.
- Chronic i.p. infusions (28- and 14-day) caused TH-positive cell loss and decreased Nurr1 mRNA, but not striatal fiber density.
- Only the 14-day chronic i.p. infusion protocol induced alpha-synuclein inclusions in TH-positive neurons.
Conclusions:
- The 14-day chronic MPTP i.p. infusion protocol is the most effective in modeling early-stage Parkinson's disease.
- This method accurately reproduces key pathological features, including dopaminergic neurodegeneration and alpha-synuclein aggregation.
- Findings provide a refined approach for preclinical PD research using MPTP mouse models.
